| 2026年中报 | 2025年年报 | 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 对外授权收入(元) | - | - | - | - | 82,324.53 |
| 推广费收入(元) | - | - | 1,529,546.63 | - | 21,450,946.82 |
| 药品销售收入(元) | 3,268,055,123.67 | - | 2,372,212,845.71 | - | 1,554,925,368.87 |
| 技术授权(元) | 51,709,846.01 | 26,602,330.64 | - | 52,302,144.19 | - |
| 抗肿瘤类产品(元) | - | 5,160,491,011.65 | - | 3,505,586,692.42 | - |
| 其他(元) | - | - | 20,187.06 | - | - |
| 营业成本(元) | |||||
| 对外授权收入(元) | - | - | - | - | 32,428.70 |
| 推广费收入(元) | - | - | 15,237,701.83 | - | 17,864,882.04 |
| 药品销售收入(元) | 126,897,262.05 | - | 59,139,892.31 | - | 50,931,139.96 |
| 技术授权(元) | 43,933,264.80 | 24,079,141.42 | - | 35,445,528.69 | - |
| 抗肿瘤类产品(元) | - | 140,500,611.53 | - | 108,040,298.55 | - |
| 其他(元) | - | - | - | - | - |
| 毛利(元) | |||||
| 对外授权收入(元) | - | - | - | - | 49,895.83 |
| 推广费收入(元) | - | - | -13,708,155.20 | - | 3,586,064.78 |
| 药品销售收入(元) | 3,141,157,861.62 | - | 2,313,072,953.40 | - | 1,503,994,228.91 |
| 技术授权(元) | 7,776,581.21 | 2,523,189.22 | - | 16,856,615.50 | - |
| 抗肿瘤类产品(元) | - | 5,019,990,400.12 | - | 3,397,546,393.87 | - |
| 其他(元) | - | - | 20,187.06 | - | - |
| 毛利率(%) | |||||
| 对外授权收入(%) | - | - | - | - | 60.61 |
| 推广费收入(%) | - | - | -896.22 | - | 16.72 |
| 药品销售收入(%) | 96.12 | - | 97.51 | - | 96.72 |
| 技术授权(%) | 15.04 | 9.48 | - | 32.23 | - |
| 抗肿瘤类产品(%) | - | 97.28 | - | 96.92 | - |
| 其他(%) | - | - | - | - | - |
| 收入构成(%) | |||||
| 对外授权收入(%) | - | - | - | - | 0.01 |
| 推广费收入(%) | - | - | 0.06 | - | 1.36 |
| 药品销售收入(%) | 98.44 | - | 99.93 | - | 98.63 |
| 技术授权(%) | 1.56 | 0.51 | - | 1.47 | - |
| 抗肿瘤类产品(%) | - | 99.49 | - | 98.53 | - |
| 其他(%) | - | - | 0.00 | - | - |
| 毛利构成(%) | |||||
| 对外授权收入(%) | - | - | - | - | 0.00 |
| 推广费收入(%) | - | - | -0.60 | - | 0.24 |
| 药品销售收入(%) | 99.75 | - | 100.60 | - | 99.76 |
| 技术授权(%) | 0.25 | 0.05 | - | 0.49 | - |
| 抗肿瘤类产品(%) | - | 99.95 | - | 99.51 | - |
| 其他(%) | - | - | 0.00 | - | - |